{"entity":{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","aka":[],"tldr":"A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting.","summary":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC is a phase 2 interventional study registered as NCT07562581 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 48 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-06. Interventions recorded: luvometinib + anlotinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07562581","url":"https://clinicaltrials.gov/study/NCT07562581"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["anlotinib"],"companies":["shanghai-fosun-pharmaceutical-industrial-development"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07562581","phase":"2","setting":"A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","participation":[{"nct":"NCT07562581","source":"https://clinicaltrials.gov/study/NCT07562581","fetchedAt":"2026-10-07T16:55:48.977Z","studySha256":"6c09f0084c39700a151dd57d992c88dd17e44ee50935f294751c0989f41dfca3","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-02","leadSponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-06-15","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07562581/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"}],"company":[{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/"}]}}